

PROGRAM – MONDAY 10 NOVEMBER

09:00 – 09:45 ARRIVAL, REGISTRATION, AND BREAKFAST

09:45 – 10:00 Welcome and status from the Center Management

Claus Lindbjerg Andersen

Professor, Center Director, Department of Molecular Medicine, Aarhus University Hospital

Lars Dyrskjøt

Professor, Center Vice Director, Department of Molecular Medicine, Aarhus University Hospital

SESSION 1: Early Detection & Screening

Chair: Lars Dyrskjøt

10:00 – 10:10 DETECT-DK: Early detection of lung cancer by blood samples – A prospective national observational study

Sara Witting Christensen Wen

MD, PhD, Department of Oncology, Lillebaelt Hospital

10:10 – 10:20

The Diverticulitis Study: Circulating tumor DNA guided vs. opportunistic colonoscopy screening for CRC detection after acute colonic diverticulitis

Thomas Bjørsum-Meyer

GI-surgeon, Associate Professor, Department of Surgery, Odense University Hospital, Svendborg

10:20 – 10:30

DETECT: De novo cancer in liver transplant recipients – a ScandiaTransplant collaboration

Elías Calandra Jiménez

MSc, Bioinformatician, PhD student, Department of Molecular Medicine, Aarhus University Hospital

SESSION 2: Treatment Monitoring & Response

Chair: Claus Lindbjerg Andersen

10:30 – 10:40

Rectal Polyp ctDNA Study: ctDNA Assessment of Large Rectal Polyps – An Observational Cohort Study

Nis Schlesinger

Consultant, Department of Surgery, Copenhagen University Hospital, Bispebjerg

10:40 – 10:50

The use of ctDNA in an organ preserving strategy in esophageal cancer

Morten Mau-Sorensen

Consultant, Department of Oncology, Copenhagen University Hospital, Rigshospitalet

10:50 – 11:00

LUCAGEN: Early Detection of Treatment Failure by Circulating Tumor DNA in Advanced non-small Cell Lung Cancer

Malene Støchkel Frank

Associate Professor, Consultant, Department of Clinical Oncology and Palliative Care, Zealand University Hospital

11:10 – 11:20

BREAK

11:20 – 11:30

LiMe-Lung: Close Monitoring of Treatment Response of Patients with Metastatic Non-Small Cell Lung Cancer using Liquid Biopsy with focus on ctDNA methylation and ctRNA PD-L1 status

Niels Pallisgaard

Professor, Department of Pathology, Zealand University Hospital

11:30 – 11:40

PRELUCA - Circulating tumor DNA guided treatment monitoring in advanced lung cancer - a randomized interventional study

Malene Støchkel Frank

Associate Professor, Consultant, Department of Clinical Oncology and Palliative Care Zealand University Hospital

11:40 – 11:50

ctDNA as Marker of Response and Recurrence in Patients with MMR-deficient Rectal Cancer Treated with Immunotherapy. A phase II Trial in Collaboration with Danish Colorectal Cancer Group (DCCG) and MOMA

Per Pfeiffer

MD, PhD, Consultant, Department of Oncology, Odense University Hospital,

11:50 – 12:00

Analyzing circulating tumor DNA as a marker for response to treatment in the NORDIC-SUN clinical trial

Iben Lyskjær Heimann

Associate Professor, Department of Molecular Medicine, Aarhus University Hospital

12:00 – 12:10

ISCOLIM: Improving Survival of Colo-rectal Liver Metastase by RFA-mediated Immuno-stimulation

Nadia Øgaard

Post doc, PhD, Department of Molecular Medicine, Aarhus University Hospital

12:10 – 12:20

Value of ctDNA for Precision Medicine in Treatment-Refractory Biliary Tract Cancer

Karen-Lise Garm Spindler

Professor, Consultant, Department of Oncology, Aarhus University Hospital

12:20 – 12:30

Validation of ctDNA elimination during chemotherapy for anal cancer

Anne Vittrup

MD, PhD-student, Department of Experimental Clinical Oncology, Aarhus University Hospital

12:30 – 13:30

LUNCH

SESSION 3: Post-Operative / Adjuvant Treatment Decision-Making

Chair: Torben Frøstrup Hansen

13:30 – 13:40

IMPROVE-pT1: Circulating Tumor-DNA for the Proper Allocation of Completion Resection in early Colorectal Cancer

Mads Falk Klein

MD, PhD, Consultant, Department of Surgery, Hvidovre Hospital



- 13:40 – 13:50** **OPTIMISE: OPTIMization of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer – a ctDNA Guided phase II Randomized Approach**
Karen-Lise Garm Spindler
Professor, Consultant, Department of Oncology, Aarhus University Hospital
- 13:50 – 14:00** **ctDNA in the NeoCol trial (Neoadjuvant chemotherapy vs. standard upfront surgery in locally advanced colon cancer: A pioneering randomized study evaluating ctDNA for guiding neoadjuvant, adjuvant therapy selection)**
Rikke Fredslund Andersen
Senior Researcher, Department of Biochemistry and Immunology, Lillebaelt Hospital
- 14:00 – 14:10** **CURE: Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer**
Cecilie Riis Iden
MD, PhD student, Department of Oncology, Copenhagen University Hospital, Rigshospitalet

SESSION 4: Method Development & Standardisation

Chair: Mads Heilskov Rasmussen

- 14:10 – 14:20** **OptiMeth: Optimization and standardization of ctDNA ddPCR methylation analyses**
Emilie Neumann Nielsen
MSc., Department of Pathology, Zealand University Hospital
- 14:20 – 14:30** **Comparison of tumor-agnostic and tumor-informed ctDNA analysis methods to predict response in patients with dMMR CRC treated with neoadjuvant pembrolizumab**
Ismail Gögenur
Professor, Consultant, Center for Surgical Science, Zealand University Hospital
- 14:30 – 14:40** **Refining Post-Surgical Management in CRC: Merging UICC TNM classification, ctDNA analyses, and digital pathology**
Salah M. Mustafa
MD, PhD student, Department of Molecular Medicine, Aarhus University Hospital
- 14:40 – 14:50** **Conclusions from the cfDNA purification QC studies, conducted in CF2.**
Martina Aabenhus Bager
MSc, Department of Pathology, Zealand University Hospital

14:50 – 15:10 BREAK with cake

SESSION 5: Surveillance & Recurrence Detection

Chair: Niels Pallisgaard

- 15:10 – 15:20** **NOAC 9: A Phase II Randomised Nordic Anal Cancer Group Study on Circulating Tumor DNA guided Follow-Up**
Karen-Lise Garm Spindler
Professor, Consultant, Department of Oncology, Aarhus University Hospital
- 15:20 – 15:30** **SUPE_R: Can follow-up after curative lung cancer treatment be improved with analysis of circulating tumor DNA?**
Lærke Rosenlund
PhD student, Department of Clinical Medicine, Aarhus University and Department of Clinical Biochemistry, Aarhus University Hospital
- 15:30 – 15:40** **RESPONSE: Colorectal cancer survivors' follow-up care – now digital and need-based. A national interventional effectiveness trial for stage I and II patients**
Mai-Britt Worm Ørntoft
MD, PhD, Department of Surgery, Regional Hospital, Gødstrup
- 15:40 – 15:50** **CIRCPAC: A National Randomized Trial Investigating the Clinical Benefit of circulating tumor DNA Guided Recurrence Surveillance After Resection for Pancreatic Cancer**
Sidsel Christy Lindgaard
MD, PhD, Post doc Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte
- 15:50 – 16:00** **ctDNA analysis of rectal cancer treated in the watchful waiting setting**
Torben Frøstrup Hansen
Professor, Consultant, Department of Oncology, Lillebaelt Hospital
- 16:00 – 16:10** **"The value of ctDNA monitoring and PRO-guided recurrence detection in patients with vulvar cancer (DaVulvaRec)**
Pernille Jensen
Professor, Consultant, Department of Gynecology and Obstetrics, Aarhus University Hospital
- 16:10 – 16:20** **CIRQUESARC: A National Prospective Observational Study of Circulating Tumor DNA and Quality of Life in Sarcomas**
Joanna Vitfell-Rasmussen, MD, PhD-student
MD, PhD student, Department of Oncology, Sarcoma Unit, Herlev and Gentofte Hospital
-
- 16:30 – 16:40** **Orientation: International symposium 21st-22nd May 2026!**
Claus Lindbjerg Andersen and Lars Dyrskjøt Andersen
-
- 16:40 – 16:45** Thank you for this last Annual Meeting
-